Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ribociclib
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 59
Trial IDs: CLEE011E2301, NCI-2014-02508, NCT02278120
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over, postmenopausal
Trial IDs: CLEE011F2301, NCI-2015-01088, NCT02422615
A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CMEK162X2114, NCI-2013-01329, NCT01781572
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2106, NCI-2013-01630, NCT01857193
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2107, NCI-2014-00139, NCT01872260
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2108, NCI-2014-01570, NCT02088684
Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011X2110C, NCI-2015-01657, NCT02292550
Ribociclib, Docetaxel. and Prednisone in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 145515, NCI-2015-01797, 15-15745, CLEE011XUS07T, NCI-2015-01701, NCT02494921
Ribociclib with Trastuzumab or Trastuzumab Emtansine in Treating Patients with Locally Advanced or Metastatic HER2-Positve Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Tissue collection/Repository
Age: 18 and over
Trial IDs: 15-530, NCI-2016-00505, NCT02657343
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011XUS29, NCI-2016-00995, NCT02732119
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLEE011XUS03, NCI-2014-02068, NCT02187783
A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression
Status: Active
Phase: Phase II
Type: Treatment
Age: 15 and over
Trial IDs: CLEE011X2201, NCI-2014-02525, 2014-000428-12, NCT02300987
Ribociclib in Treating Patients with Advanced Neuroendocrine Tumors of Foregut Origin
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0371, NCI-2015-01017, NCT02420691
Ribociclib and Letrozole in Treating Patients with Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1561, NCI-2015-02181, NCT02657928
Letrozole with or without Ribociclib before Surgery in Treating Women with Stage II-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011XUS10T, NCI-2016-00423, STUDY00002972, NCT02712723
Ribociclib and Paclitaxel in Treating Patients with Metastatic Rb+ Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCC 06115, NCI-2016-00169, NCT02599363
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: MCC-18332, NCI-2016-00241, NCT02586675
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLSZ102X2101, NCI-2016-00957, 2015-004016-38, NCT02734615
Start Over